“AbbVie Stock Plunges to 6-Week Low Despite Raised Full-Year Outlook: Profits Miss Forecasts!”
Shares of AbbVie Inc. experienced a 6.2% drop toward a six-week low in premarket trading on Thursday. Despite the biopharmaceutical company not meeting first-quarter profit expectations, it raised its full-year outlook. The disappointing Q1 performance has been attributed to increasing generic competition for its blockbuster arthritis drug, Humira. In the first quarter, AbbVie’s net income […]